Kristin Brooks03.16.21
Univercells S.A. and Gamma Biosciences have appointed Mathias Garny as the Chief Executive Officer of Univercells Technologies, a global provider of next-gen bioprocess technologies. The appointment comes as the company focuses on commercializing its product portfolio and new technology developments to further expand market reach.
Acting as General Manager, Mr. Garny has been responsible for overseeing the Company’s operations and leading the strategy development and implementation. Under his leadership, the Company introduced new products and expanded international operations.
Mr. Garny joined the company in 2015 as Chief Financial Officer to define the financial strategy and spearhead fundraising activities. He transitioned to Chief Commercial Officer in 2017, playing a key role in Univercells’ development and commercialization efforts of the technology portfolio, including the scale-X™ single-use bioreactor range and the NevoLine™ biomanufacturing platform.
In February 2020, Gamma Biosciences, a global life sciences company invested €50 million to launch Univercells Technologies following its carve-out from Univercells and accelerate the industrialization and commercialization of its manufacturing technologies.
“Mathias has demonstrated exceptional leadership as we’ve sought to aggressively grow the Univercells Technologies offer as part of the Gamma platform and across the industry. In this new role as CEO, he will further advance the company’s mission to make biologics and gene therapies more affordable through its next generation bioprocessing and manufacturing technologies,” commented Matt Gunnison, President of Gamma Biosciences.
Hugues Bultot, CEO of Univercells commented: “The Board and I are delighted to appoint Mathias as the new CEO. His background in business strategy, operations, business planning, and fundraising are key assets that will help to ensure the sustained growth of Univercells Technologies. I am confident that Mathias will bring Univercells Technologies into the next phase of growth and see his appointment as an example of the internal career progression available in our companies.”
Acting as General Manager, Mr. Garny has been responsible for overseeing the Company’s operations and leading the strategy development and implementation. Under his leadership, the Company introduced new products and expanded international operations.
Mr. Garny joined the company in 2015 as Chief Financial Officer to define the financial strategy and spearhead fundraising activities. He transitioned to Chief Commercial Officer in 2017, playing a key role in Univercells’ development and commercialization efforts of the technology portfolio, including the scale-X™ single-use bioreactor range and the NevoLine™ biomanufacturing platform.
In February 2020, Gamma Biosciences, a global life sciences company invested €50 million to launch Univercells Technologies following its carve-out from Univercells and accelerate the industrialization and commercialization of its manufacturing technologies.
“Mathias has demonstrated exceptional leadership as we’ve sought to aggressively grow the Univercells Technologies offer as part of the Gamma platform and across the industry. In this new role as CEO, he will further advance the company’s mission to make biologics and gene therapies more affordable through its next generation bioprocessing and manufacturing technologies,” commented Matt Gunnison, President of Gamma Biosciences.
Hugues Bultot, CEO of Univercells commented: “The Board and I are delighted to appoint Mathias as the new CEO. His background in business strategy, operations, business planning, and fundraising are key assets that will help to ensure the sustained growth of Univercells Technologies. I am confident that Mathias will bring Univercells Technologies into the next phase of growth and see his appointment as an example of the internal career progression available in our companies.”
